1. Introduction {#s0005}
===============

Ovarian cancer is the leading cause of death among patients with gynecologic malignancies ([@bb0025], [@bb0020], [@bb0035], [@bb0005], [@bb0060], [@bb0065], [@bb0085], [@bb0050]), most women (70--80%) present with stage III--IV disease ([@bb0025]). Largely, this results from lack of specific symptoms and reliable early detection methods.

Surgery and chemotherapy are gold standard for newly diagnosed ovarian cancer ([@bb0025], [@bb0060], [@bb0065], [@bb0080], [@bb0015], [@bb0090]). Primary debulking surgery (PDS) and surgical staging, followed by platinum/taxane chemotherapy is the standard of care ([@bb0025], [@bb0035]). Recently, studies on neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) for advanced ovarian cancer question the standard approach ([@bb0025], [@bb0020], [@bb0060], [@bb0065], [@bb0085], [@bb0080], [@bb0015], [@bb0090], [@bb0075], [@bb0045]).

Residual disease is a well-known prognostic factor for survival, justifying extensive cytoreductive surgery ([@bb0025], [@bb0020], [@bb0005], [@bb0010]). Patients benefit most from surgical intervention when complete cytoreduction is achieved ([@bb0035]). This is often difficult based on disease burden, location, and medical co-morbidities ([@bb0025]). No single modality consistently and accurately predicts complete cytoreduction, nor identifies patients who benefit most from surgical intervention.

Retrospective studies show NACT/IDS requires less radical procedures than PDS and results in higher rates of complete resection, less mortality and equivalent overall survival ([@bb0020], [@bb0060], [@bb0065], [@bb0080], [@bb0015], [@bb0090], [@bb0075]). However, several studies failed to demonstrate benefit of IDS among patients whose disease couldn\'t be optimally debulked after 3 courses of chemotherapy ([@bb0020], [@bb0070]). Both the EORTC and CHORUS trials where PDS/chemotherapy and NACT/IDS were studied, demonstrated survival with NACT/IDS was not inferior to PDS/chemotherapy for patients with stage IIIC-IV disease ([@bb0085], [@bb0045]).

Originally, this survey was sent in 2010, prior to publication of above clinical trials. In 2010, most responding Society of Gynecologic Oncologists (SGO) members didn\'t treat patients with NACT/IDS, nor did they consider available evidence sufficient to support this approach ([@bb0025]). SGO members were re-surveyed to assess patterns of care regarding NACT/IDS for advanced ovarian, fallopian tube, and primary peritoneal carcinoma. Our objective was to identify patterns of care in advanced ovarian cancer and compare them to responses in 2010.

2. Methods/materials {#s0010}
====================

The Rush University Institutional Review Board (15042003-IRB01) approved of this study and it was completed through administration of a non-validated electronic survey. We utilized the same electronic survey from 2010 ([Supplemental Fig. 1](#ec0005){ref-type="supplementary-material"}). We assessed demographics, practice characteristics, current opinions, initial approaches to management of ovarian cancer, and evaluated indications for NACT/IDS. Membership list was obtained from SGO by completion of their online E-survey application. The 20-item survey was distributed in English to working e-mail addresses (n = 1835), and results were collected using commercially available online software (<http://www.surveymonkey.com>). An opt-out option was provided.

Demographics were summarized with descriptive statistics. Statistical analysis was performed using frequency distributions and Chi-square test to detect differences between groups. Data from 2015 was assumed independent from 2010.

3. Results {#s0015}
==========

3.1. Demographics {#s0020}
-----------------

267 responses were obtained from 1835 working e-mail addresses (response rate, 15%). Recipients who opted out (n = 112) were not included in analysis. Most were male (56%) and with \> 15 years experience (35%) ([Table 1](#t0005){ref-type="table"}). Most were gynecologic oncologists; 2.5% identified as medical oncologists. Most, (60%) identified practice type as "academic", 24% as "private with academic affiliation", 13% as "private", 2% as "military", and 1% as "other". Most, (89%) practice in the USA, 1% in Canada, 4% in Europe and 6% in Asia, Central/South America or Australia/New Zealand ([Table 1](#t0005){ref-type="table"}). Majority (80%) manages ovarian cancer both as a surgeon and oncologist; 17% state role limited to surgical intervention ([Table 1](#t0005){ref-type="table"}). Many (42%) state they see 5--15 new patients with ovarian cancer per month and 44% reported \< 5 new patients per month.Table 1Demographics of respondents.Table 120102015N%N%1. *Years of practice since fellowship*[a](#tf0005){ref-type="table-fn"}, [b](#tf0010){ref-type="table-fn"}Fellow in-training267.7239.2\< 5 years7722.87429.55--10 years5616.64417.511--15 years4413.1239.2\> 15 years13439.88734.7  2. *Specialty*[a](#tf0005){ref-type="table-fn"}Gynecologic oncology33198.224597.6Medical oncology61.862.4Radiation oncology0000  3. *Current practice type*[a](#tf0005){ref-type="table-fn"}Academic19659.214859Private with academic affiliation86266124.3Private43133212.8Military61.841.6  4. *Location*[a](#tf0005){ref-type="table-fn"}, [b](#tf0010){ref-type="table-fn"}USA31894.622388.8Canada41.220.8Europe82.4103.98Other61.8166.4  5. *Gender*[a](#tf0005){ref-type="table-fn"}, [b](#tf0010){ref-type="table-fn"}Male22466.714156.2Female11333.311043.8[^1][^2]

3.2. Self-reported rates {#s0025}
------------------------

Most stated rate of optimal primary cytoreduction \> 60%, 35% reported a rate between 61 and 80% and 41% reported a rate \> 80% ([Table 2](#t0010){ref-type="table"}). Only 15% identified rate \< 60% ([Table 2](#t0010){ref-type="table"}). A significant difference of reported optimal cytoreduction was found between males/females, years of experience, but not practice type ([Table 2](#t0010){ref-type="table"}). Of note, corresponding data from 2010 can be found in [Supplemental Fig. 2](#ec0010){ref-type="supplementary-material"}.Table 2Responses to selected questions according to years of experience, practice type and sex.Table 2Years of experiencePractice typeSexFellow\< 10 years\> 10 yearsPrivatePrivate w/affiliationMilitary/otherAcademicMaleFemale1. *Rate of optimal primary cytoreduction*[a](#tf0015){ref-type="table-fn"}\< 20%0 (0%)2 (1.8%)1 (1%)1 (3.2%)0 (0%)0 (0%)2 (1.4%)1 (0.7%)2 (1.9%)21--40%0 (0)%3 (2.8%)2 (1.9%)0 (0%)2 (3.5%)0 (0%)3 (2.1%)3 (2.2%)2 (1.9%)41--60%3 (13.6%)15 (13.8%)10 (9.6%)3 (9.7%)10 (17.2%)1 (10%)14 (9.9%)20 (14.7%)8 (7.6%)61--80%6 (27.3%)34 (31.2%)44 (42.3%)14 (45.2%)19 (32.8%)5 (50%)46 (32.4%)53 (39.0%)31 (29.5%)\> 80%9 (40.9%)46 (42.2%)45 (43.2%)12 (38.7%)25 (43.1%)3 (30%)60 (42.3%)52 (38.2%)48 (45.7%)I don\'t know4 (18.2%)9 (8.3%)2 (1.9%)0 (0%)2 (3.5%)0 (0%)13 (9.2%)4 (2.9%)11 (10.5%)  2. *Percentage of your patients who receive NACT*None0 (0%)2 (1.8%)1 (0.9%)0 (0%)1 (1.7%)0 (0%)2 (1.4%)2 (1.5%)1 (1%)1--10%2 (10%)18 (15.9%)39 (36.8%)7 (22.6%)23 (39.7%)1 (10%)28 (20%)38 (27.9%)21 (20.4%)11--15%7 (35%)47 (41.6%)39 (36.8%)11 (35.5%)19 (32.8%)6 (60%)57 (40.7%)47 (34.6%)46 (44.7%)26--40%10 (50%)33 (29.2%)16 (15.1%)9 (29.0%)9 (15.5%)1 (10%)40 (28.6%)34 (25%)25 (24.3%)41--60%0 (0%)11 (9.7%)9 (8.5%)2 (6.5%)5 (8.6%)2 (20%)11 (7.9%)13 (9.6%)7 (6.8%)61--75%1 (5%)2 (1.8%)2 (1.9%)2 (6.5%)1 (1.7%)0 (0%)2 (1.4%)2 (1.5%)3 (2.9%)\> 75%0 (0%)0 (0%)0 (0%)0 (0%)0 (0%)0 (0%)0 (0%)0 (0%)0 (0%)  3. *Accurately determine pre-op if a patient can be optimally cytoreduced*Yes7 (35%)38 (33.6%)38 (35.8%)11 (35.5%)25 (43.1%)4 (40%)43 (30.7%)43 (31.6%)40 (38.8%)No8 (40%)51 (45.1%)60 (56.6%)13 (41.9%)28 (48.3%)6 (60%)72 (51.4%)80 (58.8%)39 (37.9%)I don\'t know5 (25%)24 (21.2%)8 (7.5%)7 (22.6%)5 (8.6%)0 (0%)25 (17.9%)13 (9.6%)24 (23.3%)[^3]

Most (64%) used NACT between 11 and 40% of the time for treatment of stage IIIC/IV disease, 25% used NACT \< 10%, and 11% used NACT \> 40% of the time for treatment of stage IIIC/IV disease ([Table 2](#t0010){ref-type="table"}).

3.3. Diagnosis {#s0030}
--------------

Many, (50%) didn\'t think it possible to predict optimal cytoreduction pre-operatively; when asked which modality is most helpful, 59% identified CT scan, 24% said diagnostic laparoscopy and 0.5% said CA-125.

Many respondents (95%) identified medically inoperable candidates, patients with unresectable intraparenchymal liver disease (82%), and women with bulky upper abdominal disease on pre-operative imaging (63%) as likely to benefit from NACT/IDS. Only 8% thought patients with extreme values of CA-125 were likely to benefit.

3.4. Treatment {#s0035}
--------------

All respondents would use carboplatin/paclitaxel for NACT. Number of cycles to give prior to surgery varied; 54% said 3 cycles, 42% said it would depend on response ([Table 3](#t0015){ref-type="table"}). Many (47%), believed patients who received NACT with complete response should undergo an exploratory laparotomy with total abdominal hysterectomy (TAH) and bilateral salpingo-oophorectomy (BSO) even in the absence of gross disease ([Table 3](#t0015){ref-type="table"}). Others (39%) stated patients should undergo laparoscopic exploration with total laparoscopic hysterectomy (TLH) and BSO in the absence of gross disease ([Table 3](#t0015){ref-type="table"}).Table 3Responses to treatment questions.Table 320102015N%[a](#tf0020){ref-type="table-fn"}N%[a](#tf0020){ref-type="table-fn"}1. How many cycles before you operate?Standard 3 cycles17353.612853.8Standard 4 cycles216.572.9Variable; depends on response13541.810142.56 cycles or more51.520.8  2. After NACT with a complete response, you:LSC exploration, cytoreduction only if gross disease123.8114.7Ex-lap, cytoreduction if gross residual268.293.8LSC exploration, TLH/BSO even in absence of gross disease[b](#tf0025){ref-type="table-fn"}6620.89239.2Ex lap with TAH/BSO even in absence of gross disease[b](#tf0025){ref-type="table-fn"}22570.811147.2Not undergo surgical exploration51.610.4Other247.5114.7  3. After NACT with gross residual on ID, you:If optimally cytoreduced place a port and treat with at least 2 IP cycles13642.29842.1If optimally cytoreduced continue IV chemo13943.27532.2Switch IV treatment to \_\_\_\_\_16520.9Treat with IP regardless of cytoreductive result10.341.7Treat with more IV regardless of cytoreductive result5918.34519.3  4. After NACT with microscopic disease on ID, you:At least 2 cycles of IP15748.99942.9Continue with same type of IV16451.511851.1Switch IV treatment to \_\_\_\_\_123.773Offer no treatment and start disease surveillance20.631.3[^4][^5][^6][^7]

If gross disease was found and optimal cytoreduction was achieved, 32% would continue with same IV chemotherapy and 42% would place a port and treat with at least two cycles of intraperitoneal (IP) chemotherapy ([Table 3](#t0015){ref-type="table"}). Others (19%) would continue with more IV chemotherapy regardless of result ([Table 3](#t0015){ref-type="table"}).

If microscopic disease was found, 51% would continue with same IV chemotherapy treatment, and 43% would treat with at least 2 cycles of IP chemotherapy ([Table 3](#t0015){ref-type="table"}).

3.5. Evidence {#s0040}
-------------

Respondents didn\'t consider available evidence sufficient to justify NACT/IDS (68%). Additionally, the majority doesn\'t think it should be the preferred treatment (79%).

4. Discussion {#s0045}
=============

Standard of care for newly diagnosed ovarian cancer is surgery and chemotherapy ([@bb0025], [@bb0060], [@bb0065], [@bb0080], [@bb0015], [@bb0090]); the optimal order has sparked controversy ([@bb0025], [@bb0020], [@bb0060], [@bb0065], [@bb0085], [@bb0080], [@bb0015], [@bb0090], [@bb0045]). Our objective was to determine whether opinions have changed regarding the use of NACT/IDS in advanced stage ovarian cancer among members of the SGO.

The EORTC trial by Vergote et al., randomized patients with stage IIIC/IV epithelial ovarian cancer to PDS/chemotherapy or NACT/IDS ([@bb0020], [@bb0085]). Overall survival (OS) and progression free survival (PFS) were similar in both groups with median OS being 29 and 30 months respectively ([@bb0085]). Median PFS in both groups was 12 months ([@bb0085]). Authors concluded NACT/IDS was not inferior to PDS/chemotherapy for patients with stage IIIC/IV disease ([@bb0085]).

The CHORUS trial by Kehoe et al., randomized women with suspected stage III/IV ovarian cancer to PDS/chemotherapy or NACT/IDS ([@bb0045]). Survival was similar in both groups although lower than predicted ([@bb0045]). Median OS was 22.6 months and 24.1 months respectively ([@bb0045]). Median PFS was 12 v 10.7 in favor of the NACT/IDS group ([@bb0045]). Authors concluded survival with NACT/IDS was non-inferior to PDS/chemotherapy in stage III/IV disease ([@bb0045]).

A large retrospective study by Chiva et al. compared the survival impact of complete cytoreduction after PDS and IDS in patients with advanced ovarian cancer ([@bb0020]). Of patients reviewed, 87% underwent PDS and 16.3% NACT/IDS ([@bb0020]). One third were considered completely resected with microscopic disease ([@bb0020]). After PDS, weighted average of median OS and PFS was 43 and 17 months, respectively ([@bb0020]). After IDS, median OS and PFS were 33 and 14 months ([@bb0020]). Authors concluded IDS didn\'t improve nor ensure equal benefit of complete PDS ([@bb0020]).

A substantial fraction of members use intraperitoneal (IP) chemotherapy to complete therapy for women with gross (42%) or minimal (43%) disease after NACT/IDS; this has slightly declined since 2010 where 42% would treat gross disease and 49% would treat residual disease with IP chemotherapy. Results of the OV21/PETROC study demonstrate use of IP carboplatin following NACT/IDS is well tolerated and associated with lower PD9 rate compared to IV therapy, supporting our results ([@bb0055]).

Fewer respondents feel they cannot accurately predict pre-operatively whether a patient can be optimally cytoreduced (50% in 2015, 62% in 2010) ([@bb0025]). CT scan remains most helpful (59% in 2015, 63% in 2010), diagnostic laparoscopy has increased in favor (24% in 2015, 19% in 2010) while CA-125 has decreased (0.5% in 2015, 18% in 2010) ([@bb0025]). Existing studies highlight diagnostic laparoscopy for assessing feasibility of optimal PDS/IDS. The Fagotti laparoscopy-based scoring system is a validated predictive index using the distribution of intra-abdominal disease for prediction of optimal cytoreduction. Cost of implementation is a concern and should serve as a hypothesis for future studies ([@bb0030], [@bb0040]).

Demographics of respondents are somewhat different from 2010. Notably, proportion of men to women, and increase in respondents from Central/South America or Australia/New Zealand ([Table 1](#t0005){ref-type="table"}) ([@bb0025]). Demographics are overall consistent with the membership distribution of the SGO, with majorities from the USA identifying as academic gynecologic oncologists. Observed differences are likely secondary to response rates (15% in 2015, 30% in 2010).

Respondents reported a remarkably high number of new cases each month; 42% reported 5--15 new patients each month (47% in 2010). This extrapolates to 6720--20,160 new patients with ovarian cancer seen by 112 providers each year; a gross over-estimate as only an estimated 21,000 new cases were diagnosed in the US in 2015. This was also true in 2010.

Perceived rates of optimal cytoreduction were high, with 42% stating complete cytoreduction rate \> 80%, and 35% stating rate was 61--80% ([Table 2](#t0010){ref-type="table"}). High reported cytoreduction rates were also seen in 2010 where 42% stated rate between 61 and 80% and 39% stated \> 80%. This too is a gross overestimate as this level of complete cytoreduction is likely unattainable. Perceived rates of optimal cytoreduction were similar between less (\< 10 years) and more experienced (\> 10 years) respondents with perceived rates being 41% and 42% respectively ([Table 2](#t0010){ref-type="table"}). This differs from 2010 where perceived rates were 15% more in less experienced respondents ([@bb0025]). This was thought to be due to aggressive surgical debulking being a newer trend ([@bb0025]). Rates of optimal cytoreduction were different between men/women ([Table 2](#t0010){ref-type="table"}). This was not seen in 2010 ([@bb0025]) and likely results from different response rates, but does warrant further investigation.

NACT/IDS is utilized more than in 2010; roughly 60% used NACT \< 10% in 2010 only 25% of respondents use NACT \< 10% of the time now ([Table 2](#t0010){ref-type="table"}) ([@bb0025]). Use of NACT/IDS was similar among respondents identifying as "academic" and "private" where 20% and 22%, respectively, used NACT \< 10% of the time ([Table 2](#t0010){ref-type="table"}). This differs from 2010 where 70% of "private" and 56% of "academic" respondents used NACT \< 10% ([@bb0025]). Generalizability of these results is difficult due to significantly fewer "private" participants, as was true in 2010 ([@bb0025]).

Many (47%) would perform an exploratory laparotomy with TAH-BSO in the absence of gross visible disease (71% in 2010) ([Table 3](#t0015){ref-type="table"}) ([@bb0025]). Others (39%) would perform a TLH-BSO in the absence of gross visible disease (21% in 2010) ([Table 3](#t0015){ref-type="table"}) ([@bb0025]). The differences in both laparoscopic v open abdominal approach between 2010 and 2015 were statistically significant and demonstrates the increasing role of laparoscopy ([@bb0035]).

Our study has several limitations. Questions were developed by the authors, and not validated. Lack of validation makes misinterpretation possible. In addition, our response rate was only 15% making it difficult to generalize findings. Additionally, majority of respondents practice in academic settings, making our results biased, representing a more academic picture. While this limitation is important to note, most SGO members practice in an academic setting.

Despite published randomized controlled trials and retrospective reviews of NACT/ID versus PDS/chemotherapy, most SGO members don\'t utilize this approach, nor do they consider evidence sufficient to support regular use. This was true in 2010; however, fewer respondents feel evidence is insufficient to support use of NACT/IDS (68% 2015, 82% 2010) ([@bb0025]). In this selected survey population, primarily based in the U.S., it appears we are still biased against the use of NACT/IDS; however this may be slowly changing as evidenced by the 2010 study. Barriers to greater implementation of NACT/IDS into regular practice should be evaluated in future studies. The results of our study should be used as a benchmark to continue monitoring practice patterns in the treatment of ovarian cancer.
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[^1]: 15 non-respondents.

[^2]: Variance in response based on years of practice since fellowship, location, and gender was statistically significant *p*-value \< 0.05.

[^3]: Variance in response based on experience level and gender was statistically significant *p* \< 0.05.

[^4]: Key

[^5]: LSC = laparoscopic; TLH = total laparoscopic hysterectomy; BSO = bilateral salpingo-oophorectomy; TAH = total abdominal hysterectomy; IV = intravenous; IP = intra-peritoneal.

[^6]: Percentages are based on the number of participants responding to each question, some participants marked multiple answers.

[^7]: denotes statistically significant difference between years *p* \< 0.0001 by two-sample *t*-test.
